CHAN, Timothy,WOLCHOK, Jedd,MAKAROV, Vladimir,SNYDER CHAREN, Alexandra
申请号：
EP14876694
公开号：
EP3090066A4
申请日:
2014.12.23
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy. The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy can be predicted. The present invention further comprises the discovery that cancer cells may harbor somatic mutations that result in neoepitopes that are recognizable by a patients immune system as non-self. The identification of one or more neoepitopes in a cancer sample is useful for determining which cancer patients are likely to respond favorably to immunotherapy, in particular, treatment with an immune checkpoint modulator.
